Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Proposes Setting Key Drugs as Category Separated from Bundled Trades
The Ministry of Health, Labor and Welfare (MHLW) on September 28 proposed revising its distribution guidelines to set drugs with high medical needs as a category of products that should be excluded from bundled transactions involving across-the-board discounts. The Guidelines…
To read the full story
Related Article
- Japan’s Revised Drug Distribution Guidelines Take Effect
March 4, 2024
- Ryukaikon OKs Revised Distribution Guidelines, Pharmas Urged to Explain Rationale of Solo Wholesaler Policy
December 22, 2023
- Guidelines Should Urge Drug Makers to Explain Solo-Wholesaler Decisions: Panel Members
September 29, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
REGULATORY
- MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…